David J. Parsley

Array ( [id] => 16557498 [patent_doc_number] => 20210002646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => DNMT3B GENE-DEFICIENT CHO CELL LINE, PREPARATION AND APPLICATIONS THEREOF AND RECOMBINANT PROTEIN EXPRESSION SYSTEM USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/862664 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16862664 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420669 [patent_doc_number] => 20200345867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => ORGAN DIRECTED GENE DELIVERY [patent_app_type] => utility [patent_app_number] => 16/864130 [patent_app_country] => US [patent_app_date] => 2020-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17905 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16864130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16557517 [patent_doc_number] => 20210002665 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => RNA-GUIDED GENE EDITING AND GENE REGULATION [patent_app_type] => utility [patent_app_number] => 16/858689 [patent_app_country] => US [patent_app_date] => 2020-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42734 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16858689 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16298077 [patent_doc_number] => 20200283800 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => GENE THERAPIES FOR NEURODEGENERATIVE DISEASES [patent_app_type] => utility [patent_app_number] => 16/857311 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9604 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857311 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16399184 [patent_doc_number] => 20200340042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => IN VITRO SELECTION FOR NUCLEIC ACID APTAMERS [patent_app_type] => utility [patent_app_number] => 16/857885 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857885 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16221256 [patent_doc_number] => 20200246372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-06 [patent_title] => METHODS OF TREATING MOTOR NEURON DISEASES [patent_app_type] => utility [patent_app_number] => 16/854978 [patent_app_country] => US [patent_app_date] => 2020-04-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22243 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16854978 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16361414 [patent_doc_number] => 20200318165 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => Rapid Identification of Microorganisms [patent_app_type] => utility [patent_app_number] => 16/854786 [patent_app_country] => US [patent_app_date] => 2020-04-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16281 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16854786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16391356 [patent_doc_number] => 20200332297 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-22 [patent_title] => COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 16/851679 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44494 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 403 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851679 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16361352 [patent_doc_number] => 20200318103 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => STEREODEFINED SUB-MOTIF OPTIMISATION METHODS [patent_app_type] => utility [patent_app_number] => 16/847169 [patent_app_country] => US [patent_app_date] => 2020-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847169 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18444521 [patent_doc_number] => 11680079 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-20 [patent_title] => Nucleic acid aptamers to treat histone-induced disease states [patent_app_type] => utility [patent_app_number] => 16/847585 [patent_app_country] => US [patent_app_date] => 2020-04-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 77 [patent_no_of_words] => 19887 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16847585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16437415 [patent_doc_number] => 20200354741 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => GENE-EDITING SYSTEMS FOR MODIFYING A SCN9A OR SCN10A GENE AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/845280 [patent_app_country] => US [patent_app_date] => 2020-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16845280 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16451065 [patent_doc_number] => 20200360491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => TREATMENT OF LYSOSOMAL STORAGE DISEASE IN THE EYE THROUGH ADMINISTRATION OF AAVS EXPRESSING TPP1 [patent_app_type] => utility [patent_app_number] => 16/843360 [patent_app_country] => US [patent_app_date] => 2020-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16843360 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16359473 [patent_doc_number] => 20200316224 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => Method and Kit for Treatment of Genetic Congenital Birth Defects [patent_app_type] => utility [patent_app_number] => 16/839317 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3213 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16853533 [patent_doc_number] => 20210154278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-27 [patent_title] => IMMUNE GENE-DRUGS EXPRESSED IN TUMOR CELLS ACTIVATE THE SYSTEMIC IMMUNE RESPONSE AGAINST CANCER [patent_app_type] => utility [patent_app_number] => 16/836180 [patent_app_country] => US [patent_app_date] => 2020-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3496 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 69 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16836180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16718656 [patent_doc_number] => 20210085803 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => METHOD FOR OPENING TIGHT JUNCTIONS [patent_app_type] => utility [patent_app_number] => 16/835196 [patent_app_country] => US [patent_app_date] => 2020-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16835196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506481 [patent_doc_number] => 20200385737 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72 [patent_app_type] => utility [patent_app_number] => 16/833107 [patent_app_country] => US [patent_app_date] => 2020-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45806 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16833107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17377084 [patent_doc_number] => 11235073 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-02-01 [patent_title] => Method for treating or preventing heart failure [patent_app_type] => utility [patent_app_number] => 16/826984 [patent_app_country] => US [patent_app_date] => 2020-03-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 42 [patent_no_of_words] => 16864 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 123 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16826984 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376612 [patent_doc_number] => 20200325454 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => VECTORS CONTAINING AIMP2-DX2 AND TARGET NUCLEIC ACIDS FOR miR 142 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/819998 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16819998 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16269122 [patent_doc_number] => 20200270609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-27 [patent_title] => Single-Stranded RNAI Oligonucleotides Targeting APOC-III [patent_app_type] => utility [patent_app_number] => 16/813241 [patent_app_country] => US [patent_app_date] => 2020-03-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35141 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16813241 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16298073 [patent_doc_number] => 20200283796 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-10 [patent_title] => DNA LAUNCHED RNA REPLICON SYSTEM (DREP) AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/810109 [patent_app_country] => US [patent_app_date] => 2020-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25831 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16810109 [rel_patent_id] =>[rel_patent_doc_number] =>)